Åke Borg
Principal investigator
Matched analysis of circulating selenium with the breast cancer selenotranscriptome: a multicentre prospective study
Author
Summary, in English
Introduction
Low serum selenium and altered tumour RNA expression of certain selenoproteins are associated with a poor breast cancer prognosis. Selenoprotein expression stringently depends on selenium availability, hence circulating selenium may interact with tumour selenoprotein expression. However, there is no matched analysis to date.
Methods
This study included 1453 patients with newly diagnosed breast cancer from the multicentric prospective Sweden Cancerome Analysis Network – Breast study. Total serum selenium, selenoprotein P and glutathione peroxidase 3 were analysed at time of diagnosis. Bulk RNA-sequencing was conducted in matched tumour tissues. Fully adjusted Cox regression models with an interaction term were employed to detect dose-dependent interactions of circulating selenium with the associations of tumour selenoprotein mRNA expression and mortality.
Results
237 deaths were recorded within ~ 9 years follow-up. All three serum selenium biomarkers correlated positively (p Conclusions
This first unbiased analysis of serum selenium with the breast cancer selenotranscriptome identified an effect-modification of selenium on the associations of DIO1, SELENOM, and DIO3 with prognosis. Selenium substitution in patients with DIO1-expressing tumours merits consideration to improve survival.
Low serum selenium and altered tumour RNA expression of certain selenoproteins are associated with a poor breast cancer prognosis. Selenoprotein expression stringently depends on selenium availability, hence circulating selenium may interact with tumour selenoprotein expression. However, there is no matched analysis to date.
Methods
This study included 1453 patients with newly diagnosed breast cancer from the multicentric prospective Sweden Cancerome Analysis Network – Breast study. Total serum selenium, selenoprotein P and glutathione peroxidase 3 were analysed at time of diagnosis. Bulk RNA-sequencing was conducted in matched tumour tissues. Fully adjusted Cox regression models with an interaction term were employed to detect dose-dependent interactions of circulating selenium with the associations of tumour selenoprotein mRNA expression and mortality.
Results
237 deaths were recorded within ~ 9 years follow-up. All three serum selenium biomarkers correlated positively (p Conclusions
This first unbiased analysis of serum selenium with the breast cancer selenotranscriptome identified an effect-modification of selenium on the associations of DIO1, SELENOM, and DIO3 with prognosis. Selenium substitution in patients with DIO1-expressing tumours merits consideration to improve survival.
Department/s
- LUCC: Lund University Cancer Centre
- Surgery
- Breastcancer-genetics
- Tumor Cell Biology
- Division of Translational Cancer Research
- Transl oncogenomics
- Translational Oncogenomics
- Breast cancer treatment
- The Liquid Biopsy and Tumor Progression in Breast Cancer
- Breast Cancer Surgery
- Surgery (Lund)
- Familial Breast Cancer
- EpiHealth: Epidemiology for Health
Publishing year
2023-09-23
Language
English
Publication/Series
Journal of Translational Medicine
Document type
Journal article
Publisher
BioMed Central (BMC)
Topic
- Cancer and Oncology
Status
Published
Project
- Sweden Cancerome Analysis Network - Breast (SCAN-B): a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine
Research group
- Surgery
- Tumor Cell Biology
- Translational Oncogenomics
- The Liquid Biopsy and Tumor Progression in Breast Cancer
- Breast Cancer Surgery
- Familial Breast Cancer
ISBN/ISSN/Other
- ISSN: 1479-5876